Griffithsin, alone and combined with all classes of antiretroviral drugs, potently inhibits HIV cell-cell transmission and destruction of CD4+ T cells

Journal of Antivirals and Antiretrovirals

Volumn 4, Issue 4, 2012, Pages 103-112

  Ferir, Geoffrey ^a   Palmer, Kenneth E ^b   Schols, Dominique ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b University of Louisville School of Medicine   (United States)

Author keywords

Antiretroviral drugs; Cell cell; DC SIGN; Flow cytometry combinations; Griffithsin; HIV transmission; Microbicide

Indexed keywords

BANLEC; EFAVIRENZ; ELVITEGRAVIR; ENFUVIRTIDE; ETRAVIRINE; GRIFFITHSIN; LECTIN; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 2G12; MONOCLONAL ANTIBODY B12; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY) PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; PLERIXAFOR; PRO 2000; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TENOFOVIR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL CONTACT; CELL DESTRUCTION; CELL MIGRATION; CELL SUSPENSION; CELL TRANSFER; CONTROLLED STUDY; DRUG DOSE REDUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GIANT CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; PERSISTENT VIRUS INFECTION; PROTEIN EXPRESSION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84872004279     PISSN: None     EISSN: 19485964     Source Type: Journal    
DOI: 10.4172/jaa.1000054     Document Type: Article

References (64)

1. Sattentau Q (2008) Avoiding the void: cell-to-cell spread of human viruses. Nat Rev Microbiol 6: 815-826.
2. Jolly C, Kashefi K, Hollinshead M, Sattentau QJ (2004) HIV-1 cell to cell transfer across an Env-induced, actin dependent synapse. J Exp Med 199: 283-293.
3. Tilton JC, Doms RW (2010) Entry inhibitors in the treatment of HIV-1 infection. Antiviral Res 85: 91-100.
4. Dimitrov DS, Willey RL, Sato H, Chang LJ, Blumenthal R, et al. (1993) Quantitation of human immunodeficiency virus type 1 infection kinetics. J Virol 67: 2182-2190.
5. Sourisseau M, Sol-Foulon N, Porrot F, Blanchet F, Schwartz O (2007) Inefficient human immunodeficiency virus replication in mobile lymphocytes. J Virol 81: 1000-1012.
6. Jolly C, Sattentau QJ (2005) Human immunodeficiency virus type 1 virological synapse formation in T cells requires lipid raft integrity. J Virol 79: 12088-12094.
7. Nobile C, Rudnicka D, Hasan M, Aulner N, Porrot F, et al. (2010) HIV-1 Nef inhibits ruffles, induces filopodia, and modulates migration of infected lymphocytes. J Virol 84: 2282-2293.
8. Rudnicka D, Feldmann J, Porrot F, Wietgrefe S, Guadagnini S, et al. (2009) Simultaneous cell-to-cell transmission of human immunodeficiency virus to multiple targets through polysynapses. J Virol 83: 6234-6246.
9. Sowinski S, Jolly C, Berninghausen O, Purbhoo MA, Chauveau A, et al. (2008) Membrane nanotubes physically connect T cells over long distances presenting a novel route for HIV-1 transmission. Nat Cell Biol 10: 211-219.
10. Rieder P, Joos B, Scherrer A, Kuster H, Braun D, et al. (2011) Characterization of human immunodeficiency virus type 1 (HIV-1) diversity and tropism in 145 patients with primary HIV-1 infection. Clin Infect Dis 53: 1271-1279.
11. Zhu T, Mo H, Wang N, Nam DS, Cao Y, et al. (1993) Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 261: 1179-1181.
12. Chalmet K, Dauwe K, Foquet L, Baatz F, Seguin-Devaux C, et al. (2012) Presence of CXCR4-using HIV-1 in patients with recently diagnosed infection: correlates and evidence for transmission. J Infect Dis 205: 174-184.
13. th Conference on Retroviruses and Opportunistic Infections March 5-8, 2012, Seattle, WA, USA, abstract #573.
14. Gianella S, Mehta SR, Young JA, Vargas MV, Little SJ, et al. (2012) Sexual transmission of predicted CXCR4-tropic HIV-1 likely originating from the source partner's seminal cells. Virology 434: 2-4.
15. Balzarini J (2007) Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy. Nat Rev Microbiol 5: 583-597.
16. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392: 245-252.
17. Lederman MM, Offord RE, Hartley O (2006) Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat Rev Immunol 6: 371-382.
18. Geijtenbeek TB, Kwon DS, Torensma R, Van Vliet SJ, Van Duijnhoven GC, et al. (2000) DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100: 587-597.
19. Mori T, O'Keefe BR, Sowder RC 2nd, Bringans S, Gardella R, et al. (2005) Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. J Biol Chem 280: 9345-9353.
20. Emau P, Tian B, O'keefe BR, Mori T, McMahon JB, et al. (2007) Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV microbicide. J Med Primatol 36: 244-253.
21. O'keefe BR, Vojdani F, Buffa V, Shattock RJ, Montefiori DC, et al. (2009) Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc Natl Acad Sci U S A 106: 6099-6104.
22. Pauwels R, Andries K, Desmyter J, Schols D, Kukla MJ, et al. (1990) Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343: 470-474.
23. Schols D, Pauwels R, Baba M, Desmyter J, De Clercq E (1989) Syncytium formation and destruction of bystander CD4+ cells cocultured with T cells persistently infected with human immunodeficiency virus as demonstrated by flow cytometry. J Gen Virol 70: 2397-2408.
24. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
25. Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, et al. (2002) The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. J Virol 76: 7306-7321.
26. Moore JP, Cao Y, Qing L, Sattentau QJ, Pyati J, et al. (1995) Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol 69: 101-109.
27. Purtscher M, Trkola A, Gruber G, Buchacher A, Predl R, et al. (1994) A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 10: 1651-1658.
28. Schols D, Struyf S, Van Damme J, Esté JA, Henson G, et al. (1997) Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 186: 1383-1388.
29. Swanson MD, Winter HC, Goldstein IJ, Markovitz DM (2010) A lectin isolated from bananas is a potent inhibitor of HIV replication. J BiolChem 285: 8646-8655.
30. Matthews T, Salgo M, Greenberg M, Chung J, DeMasi R, et al. (2004) Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov 3: 215-225.
31. Rusconi S, Moonis M, Merrill DP, Pallai PV, Neidhardt EA, et al. (1996) Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Antimicrob Agents Chemother 40: 234-236.
32. Balzarini J, Holý A, Jindrich J, Naesens L, Snoeck R, et al. (1993) Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob Agents Chemother 37: 332-338.
33. Young SD, Britcher SF, Tran LO, Payne LS, Lumma WC, et al. (1995) L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 39: 2602-2605.
34. Balzarini J, Pelemans H, Aquaro S, Perno CF, Witvrouw M, et al. (1996) Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication. Mol Pharmacol 50: 394-401.
35. Andries K, Azijn H, Thielemans T, Ludovici D, Kukla M, et al. (2004) TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 48: 4680-4686.
36. Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, et al. (2007) Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatmentexperienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 369: 1261-1269.
37. Shimura K, Kodama E, Sakagami Y, Matsuzaki Y, Watanabe W, et al. (2008) Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol 82: 764-774.
38. Kitchen VS, Skinner C, Ariyoshi K, Lane EA, Duncan IB, et al. (1995) Safety and activity of saquinavir in HIV infection. Lancet 345: 952-955.
39. Sato H, Orenstein J, Dimitrov D, Martin M (1992) Cell-to-cell spread of HIV-1 occurs within minutes and may not involve the participation of virus particles. Virology 186: 712-724.
40. Martin N, Welsch S, Jolly C, Briggs JA, Vaux D, et al. (2010) Virological synapse-mediated spread of human immunodeficiency virus type 1 between T cells is sensitive to entry inhibition. J Virol 84: 3516-3527.
41. Stavrou D, Mehraein P, Mellert W, Bise K, Schmidtke K, et al. (1989) Evaluation of intracerebral lesions in patients with acquired immunodeficiency syndrome. Neuropathological findings and experimental data. Neuropathol Appl Neurobiol 15: 207-222.
42. Nardacci R, Antinori A, Larocca LM, Arena V, Amendola A, et al. (2005) Characterization of cell death pathways in human immunodeficiency virusassociated encephalitis. Am J Pathol 167: 695-704.
43. Xue J, Gao Y, Hoorelbeke B, Kagiampakis I, Zhao B, et al. (2012) The role of individual carbohydrate-binding sites in the function of the potent anti-HIV lectingriffithsin. Mol Pharm 9: 2613-2625.
44. Alexandre KB, Gray ES, Mufhandu H, McMahon JB, Chakauya E, et al. (2012) The lectins griffithsin, cyanovirin-N and scytovirin inhibit HIV-1 binding to the DC-SIGN receptor and transfer to CD4(+) cells. Virology 423: 175-186.
45. Férir G, Palmer KE, Schols D (2011) Synergistic activity profile of griffithsin in combination with tenofovir, maraviroc and enfuvirtide against HIV-1 clade C. Virology 417: 253-258.
46. Férir G, Huskens D, Palmer KE, Boudreaux DM, Swanson MD, et al. (2012) Combinations of griffithsin with other carbohydrate-binding agents demonstrate superior activity against HIV type 1, HIV type 2 and selected carbohydratebinding agent resistant HIV type 1 strains. AIDS Res Hum Retroviruses 28: 1513-1523.
47. Vermeire K, Princen K, Hatse S, De Clercq E, Dey K, et al. (2004) CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro. AIDS 18: 2115-2125.
48. Gantlett KE, Weber JN, Sattentau QJ (2007) Synergistic inhibition of HIV-1 infection by combinations of soluble polyanions with other potential microbicides. Antiviral Res 75: 188-197.
49. Latinovic O, Le N, Reitz M, Pal R, DeVico A, et al. (2011) Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention. AIDS 25: 1232-1235.
50. Abela IA, Berlinger L, Schanz M, Reynell L, Günthard HF, et al. (2012) Cellcell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. PLoS Pathog 8: e1002634.
51. Chen P, Hubner W, Spinelli MA, Chen BK (2007) Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained env-dependent neutralization-resistant virological synapses. J Virol 81: 12582-12595.
52. Yee M, Konopka K, Balzarini J, Düzgünes N (2011) Inhibition of HIV-1 envmediated cell-cell fusion by lectins, peptide T-20, and neutralizing antibodies. Open Virol J 5: 44-51.
53. Huskens D, Van Laethem K, Vermeire K, Balzarini J, Schols D (2007) Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12. Virology 360: 294-304.
54. Selhorst P, Grupping K, Bourlet T, Delézay O, Ariën KK, et al. (2011) In vitro activities of candidate microbicides against cell-associated HIV. Antimicrob Agents Chemother 56: 805-815.
55. Pan C, Lu H, Qi Z, Jiang S (2009) Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first and next-generation HIV-fusion inhibitors. AIDS 23: 639-641.
56. Alexandre KB, Gray ES, Panthophlet R, Moore PL, McMahon JB, et al. (2011) Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site. J Virol 85: 9039-9050.
57. Jagodzinski PP, Wierzbicki A, Wustner J, Kaneko Y, Kozbor D (1999) Enhanced human immunodeficiency virus infection in macrophages by high-molecularweight dextran sulfate is associated with conformational changes of gp120 and expression of the CCR5 receptor. Viral Immunol 12: 23-33.
58. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329: 1168-1174.
59. Baeten J, Celum C (2012) Systemic and topical drugs for the prevention of HIV infection: antiretroviral pre-exposure prophylaxis. Annu Rev Med 64: 3.1-3.14.
60. Balzarini J, Van Herrewege Y, Vanham G (2002) Metabolic activation of nucleoside and nucleotide reverse transcriptase inhibitors in dendritic and Langerhans cells. AIDS 16: 2159-2163.
61. Sigal A, Kim JT, Balazs AB, Dekel E, Mayo A, et al. (2011) Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 477: 95-98.
62. Balzarini J, Naesens L, Verbeken E, Laga M, Van Damme L, et al. (1998) Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent. AIDS 12: 1129-1138.
63. Dobard C, Sharma S, Parikh U, Hanson D, Lipscomb J, et al. (2011) High protection against vaginal infection in macaques by PEP with gel containing RAL. Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections, Boston.
64. Kouokam JC, Huskens D, Schols D, Johannemann A, Riedell SK, et al. (2011) Investigation of griffithsin's interactions with human cells confirms its outstanding safety and efficacy profile as a microbicide candidate. Plos One 6: e22635.